| Literature DB >> 18975151 |
Kenji Hayashibara1, Hiroaki Satoh, Yoko Shinohara, Masaharu Inagaki, Takayuki Kaburagi, Toshio Hashimoto, Koichi Kurishima, Hiroichi Ishikawa, Hideo Ichimura, Takeshi Nawa, Yasunori Funayama, Takeshi Matsumura, Katsunori Kagohashi, Takeshi Endo, Kinya Furukawa, Koji Kishi, Masaaki Sumi, Koichi Kamiyama, Shigemi Ishikawa.
Abstract
Survival data for non-small cell lung cancer is typically reported from clinical trials that include patients fit enough to meet treatment criteria. The denominator of all patients from which the gefitinib-treated population is derived has rarely been reported and the impact of gefitinib on population-based outcomes is difficult to measure. We have retrospectively reviewed data of 626 patients who received gefitinib in Ibaraki Prefecture (with a population of 3 million) in Japan from July 2002 until September 2007. Overall response rate was found to 30.8%, and the median survival time was 8.0 months (95% confidence interval: 7.0-9.0 months). Female gender, good PS, and adenocarcinoma were significantly associated with prolonged survival. Adverse events were generally mild and were mostly skin reactions and diarrhea. Our population-based study has generated similar results to those previously reported in published clinical trials, which had restrictive criteria for eligible patients.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18975151 DOI： 10.1007/s12032-008-9110-y
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064